A Double-blind, Placebo-controlled, Randomized Phase 3 Pivotal Trial to Assess the Efficacy and Safety of Peanut Epicutaneous Immunotherapy With Viaskin Peanut in Peanut-allergic Children.

Trial Profile

A Double-blind, Placebo-controlled, Randomized Phase 3 Pivotal Trial to Assess the Efficacy and Safety of Peanut Epicutaneous Immunotherapy With Viaskin Peanut in Peanut-allergic Children.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Sep 2016

At a glance

  • Drugs Peanut allergy immunotherapy (Primary)
  • Indications Peanut hypersensitivity
  • Focus Registrational; Therapeutic Use
  • Acronyms PEPITES
  • Sponsors DBV Technologies
  • Most Recent Events

    • 12 Aug 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Aug 2017.
    • 27 Jun 2016 Topline results from this trial are expected in the second half of 2017, according to a DBV Technologies media release.
    • 27 Jun 2016 According to a DBV Technologies media release, status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top